BioPharma Resources

Investigational drug · Phase 3

CM313

Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia, Platelet Transfusion Refractoriness.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

6

6 still active

All registered trials

15

Any phase or sponsor naming "CM313"

First trial start

2024

Nov 11, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "CM313", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Systemic Lupus Erythematosus
  • Primary Immune Thrombocytopenia
  • Platelet Transfusion Refractoriness
  • Aplastic Anemia
  • Multiple Myeloma (MM)
  • IgA Nephropathy

Approved drugs for the same conditions: Multiple myeloma · Anemia · Immune thrombocytopenia · Lupus (SLE) · IgA nephropathy · Hematology and blood cancers · Cardiovascular and metabolic · Immunology and inflammation · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "CM313" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 8 on PubMed

Also in development for Systemic Lupus Erythematosus

  • IanalumabVAY736, VAY736 AIPhase 318 trials

    Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome

  • FrexalimabSAR441344Phase 39 trials

    Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion

  • EnpatoranM5049, M5049 dosePhase 35 trials

    EMD Serono Research & Development Institute, Inc. · Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus

  • MIL62Phase 34 trials

    Beijing Mabworks Biotech Co., Ltd. · Systemic Lupus Erythematosus, Neuromyelitis Optica Spectrum Disorder, Primary Membranous Nephropathy

  • ObexelimabPhase 34 trials

    Zenas BioPharma (USA), LLC · Systemic Lupus Erythematosus, Warm Autoimmune Hemolytic Anemia, Relapsing Multiple Sclerosis

  • Rese-celCABA-201Phase 34 trials

    Cabaletta Bio · Pemphigus Vulgaris, Systemic Sclerosis, Scleroderma

  • TQH3906Phase 34 trials

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis

  • AfimetoranBMS-986256, BLN-256Phase 32 trials

    Beeline Medicines Corporation · Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.